10:41 AM EDT, 06/13/2025 (MT Newswires) -- AstraZeneca ( AZN ) said Friday that it has entered into a research collaboration with China-based CSPC Pharmaceuticals Group, aiming to discover and develop oral therapies for chronic and immunological diseases.

Under the agreement, CSPC will receive an upfront payment of $110 million and could earn up to $1.62 billion in development milestones and $3.6 billion in sales milestones, plus single-digit royalties on annual net product sales, AstraZeneca ( AZN ) said.

The company said it will have the rights to exclusive licenses to develop and commercialize drug candidates worldwide.

The research will be led by CSPC in Shijiazhuang City using its artificial intelligence-driven drug discovery platform, AstraZeneca ( AZN ) added.

Price: 74.42, Change: -0.58, Percent Change: -0.78